NCT02423902View on ClinicalTrials.gov

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 18, 2015

Primary Completion Date

July 19, 2016

Study Completion Date

July 19, 2016

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

Ad-RTS-hIL-12

Approximately 1.0x10\^12 viral particles (vp) per injection

DRUG

Veledimex

7 oral doses of veledimex

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY